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of MeMulticenter, Randomized, Open-Label Study
Comparing the Efficacy and Safety of Micafungin versus
Itraconazole for Prophylaxis of Invasive Fungal
Infections in Patients undergoing Hematopoietic Stem
Cell Transplant
Xiaojun Huang,1 Huan Chen,1 Mingzhe Han,2 Ping Zou,3 Depei Wu,4 Yongrong Lai,5
He Huang,6 Xiequn Chen,7 Ting Liu,8 Huanling Zhu,8 Jianmin Wang,9 Jianda Hu10This multicenter, randomized, open-label phase III study compared the efficacy and safety of micafungin and
itraconazole in prophylaxis of invasive fungal infections in neutropenic patients undergoing hematopoietic
stem cell transplants in China. Micafungin (50 mg/day i.v.) or itraconazole (5 mg/kg/day p.o.) was administered
for #42 days. The primary endpoint, treatment success, was defined as no proven, probable, or suspected
invasive fungal infection through therapy and the absence of proven or probable invasive fungal infection
through the end of 4 weeks after therapy. Noninferiority of micafungin against itraconazole was established
if the lower boundary of the 95% confidence interval (CI) was.10%. Of 287 patients, 283 were evaluable for
efficacy (136 for micafungin, 147 for itraconazole, intent-to-treat population). Treatment success was docu-
mented in 92.6% (126 of 136) of micafungin-treated patients and 94.6% (139 of 147) of itraconazole-treated
patients (95% CI, 27.562% to 3.482%; P 5 .48), indicating noninferiority of micafungin against itracona-
zole. Results were similar for patients treated per protocol. Whereas the rates of proven or probable
invasive fungal infection were numerically higher with micafungin than itraconazole at 4.4% (6 of 136) and
1.4% (2 of 147), rates of suspected invasive fungal infection were similar at 5.9% (8 of 136) and 7.5% (11
of 147), respectively. More patients treated with micafungin than itraconazole completed the study
(82.9% versus 67.3%, respectively). Significant differences in incidence of withdrawal due to an adverse
event (4.4% versus 21.1%) and drug-related adverse events (8% versus 26.5%) were shown between mi-
cafungin and itraconazole (P 5 .00, chi-square test). Micafungin was as effective as itraconazole in pre-
venting invasive fungal infections in patients with neutropenia. In comparison to itraconazole,
treatment tolerance was much better with micafungin.
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Candida and Aspergillus species fungal infections
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commonly used in high-risk patients.
Fluconazole is the most widely used antifungal
agent and it is recommended for prophylaxis of
Candida infections for HSCT recipients during the
period of neutropenia until engraftment. Candida
resistance to fluconazole has emerged and fluconazole
lacks activity against molds including Aspergillus. In
contrast to fluconazole, the broad-spectrum triazole,
itraconazole, has shown activity againstAspergillus spe-
cies or other molds in HSCT recipients [1,2].
By comparison, the echinocandin micafungin,
which exerts its antifungal activity by inhibiting the
production of beta-1,3-glucan, has shown antifungal
activity against both Candida and Aspergillus species.
In a randomized, double-blind study, the effectiveness
of micafungin in providing prophylaxis against proven,
probable, or suspected systemic fungal infection in
HSCT recipients was significantly higher than the
gold standard, fluconazole (80% versus 74%, respec-
tively; P 5 .03) [3]. The use of micafungin has proven
to be effective, safe, and well-tolerated [4] with few
known drug interactions [5], which are important con-
siderations when implementing antifungal prophylaxis
in HSCT recipients.
Itraconazole is currently the only agent for pro-
phylaxis of invasive fungal infections approved by the
State Food and Drug Administration in China. A
direct comparison of the efficacy and safety of mica-
fungin against itraconazole for antifungal prophylaxis
in HSCT recipients, as reported in a randomized clin-
ical trial, could not be identified before designing this
study.
The objective of this randomized, controlled, clin-
ical study was to compare the treatment success of mi-
cafungin and itraconazole in preventing invasive
fungal infections during prophylactic therapy and up
to 4 weeks after discontinuation of prophylaxis anti-
fungal therapy in HSCT recipients. The safety and
tolerability of each treatment were assessed.METHODS
Study Design
This was an open, randomized, phase III, multi-
center, parallel group study to evaluate and compare
the efficacy and safety of micafungin and itraconazole
for prophylaxis of invasive fungal infection in patients
undergoing HSCT. The duration of the study was 10
weeks. Study procedures were reviewed and approved
by the institutional review boards at each of the 10
study centers in China. Conduct of the study was in ac-
cordance with the ethical principles that have their or-
igins in the Declaration of Helsinki.
Randomization to the study medication group
(micafungin) or to the control group (itraconazole)was 1:1 by block randomization using randomization
codes generated by SAS PROC Plan. The randomiza-
tion table was developed by Excel Pharma Studies, Inc.
(Beijing, China). Randomization was stratified by
patient age (18-49 and $50 years) and type of stem
cell transplant (SCT).
Patients
Eligible for the study were adult patients, 18 to 70
years old, undergoing allogeneic or autologous HSCT
for treatment of a malignancy. Patients were free of
liver disease (serum glutamic oxaloacetic or pyruvic
transaminase greater than 5 times the normal value,
total bilirubin .2.5 times the normal value), the
existence of active, deep, or disseminated fungal infec-
tion, and known allergy to azoles or echinocandin
antifungal agents. Patients were excluded if they had
received any antifungal therapy within 72 hours of
the first dose of the study drug. Written informed
consent was provided before randomization.
Intervention
The study drug, micafungin (Astellas Pharma Inc.,
Deerfield, IL) was administered i.v. at a dose of 50 mg/
day. The control drug, itraconazole (Janssen Pharma-
ceuticals, Inc., Titusville, NJ) was administered as a
solution taken orally at a dose of 5 mg/kg/day (in 2
administrations). Patients were to receive the assigned
therapy during the neutropenic (ie, pre-engraftment)
phase of HSCT, starting within 48 hours of the begin-
ning of the transplant-related conditioning regimen
until the earliest of the following: #5 days after
engraftment (defined as an absolute neutrophil count
of $500 cells/mm3 after the nadir absolute count);
treatment day 42 after HSCT; development of proven,
probable, or suspected invasive fungal infection; devel-
opment of unacceptable drug toxicity; death; with-
drawal from study participation (patient’s decision);
or discontinuation of study treatment (investigator’s
decision).
Outcomes
Patients were evaluated at baseline, during prophy-
lactic treatment, at the end of treatment, and at 4 weeks
after prophylactic treatment, as depicted in the study
flow chart (Figure 1). The primary endpoint, treat-
ment success, was defined as the absence of proven,
probable, or suspected systemic fungal infection
through the end of prophylactic therapy and as the
absence of a proven or probable systemic fungal infec-
tion through the end of the 4-week posttreatment pe-
riod. Both criteria must have been fulfilled to achieve
treatment success.
According to the Chinese criteria for invasive fun-
gal infection diagnosis [6], proven infection was
defined as biopsy-proven invasive or disseminated
Figure 1. Study flow diagram.
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mented if bronchoscopy with bronchoalveolar lavage
revealed fungal elements in conjunction with compat-
ible clinical and computerized tomography findings.
An invasive fungal infection was defined as suspected
if fever (temperature $38.5C) persisted for .96
hours during the neutropenic phase, despite broad-
spectrum antibacterial therapy, and led to the initia-
tion of empirical antifungal therapy.
The secondary endpoints were the incidence of
proven, probable, or suspected invasive fungal infec-
tion through the end of prophylactic therapy (treat-
ment failure); the incidence of proven or probable
invasive fungal infection at any time during the study;
the incidence of proven, probable, or suspected inva-
sive fungal infection after prophylactic therapy in pa-
tients who did not have a fungal infection during
prophylaxis therapy; incidence by organism of invasive
fungal infection; incidence of suspected fungal infec-
tion during the study; the rate of use of antifungal
agents during the 4 weeks after study medication ad-
ministration; time to treatment failure; time to
suspected invasive fungal infection; incidence of super-
ficial fungal infections during active antifungal treat-
ment; incidence of fungal colonization at baseline
and at the end of prophylactic therapy; or patient
survival. Safety assessments included adverse event
reporting, results of clinical laboratory tests, and vital
signs. Hematology and serum chemistry analyses and
fungal surveillance cultures were performed at the
study sites at baseline, at least twice weekly during
the administration of antifungal therapy, and on the
final day of prophylactic therapy.
Temperature was monitored on a daily basis.
Evaluation of the patient for fungal infection, fungal
cultures of the oropharynx, urine, and perirectum or
stool, and radiographic scans of the chest were
conducted at baseline, on a weekly basis duringprophylactic therapy, on the last day of prophylactic
therapy, and at 4 weeks after discontinuation of
prophylactic therapy.Statistical Analysis
Data were analyzed for the intent-to-treat popula-
tion (all patients who had taken at least 1 dose of pro-
phylactic antifungal therapy and had at least 1
endpoint measurement after administration of anti-
fungal therapy) and for the per protocol set (all patients
treated per protocol without major protocol devia-
tions). The primary efficacy analysis was based on
the intent-to-treat population and on the per protocol
set. The safety set (all patients who had taken at least 1
dose of prophylactic antifungal therapy) was used for
the analysis of safety data. Efficacy results are pre-
sented for the intent-to-treat population, unless noted
otherwise, and safety results are presented for the
safety set.
For the primary analysis of treatment success,
micafungin was considered not to be statistically infe-
rior to itraconazole if the 95% lower confidence
boundary on the difference in success rates between
micafungin and itraconazole was more than 210%.
Micafungin was considered superior to itraconazole
if the lower boundary was greater than 0%. The
Cochrane-Mantel-Haenszel chi-square test was used
to test the difference in distribution between treatment
groups. The rate of treatment success was analyzed by
stratification of patient age (18-49 and $50 years) and
type of HSCT. The level of significance was 2.5% for
the 1-sided test; confidence intervals (CIs) were
2-sided at the 95% level. Data missing for the primary
endpoint were imputed using the last observation
carried forward and observed case methods.
Secondary endpoints were analyzed using the
Cochrane-Mantel-Haenszel test. Time to treatment
Figure 2. Patient flow through the study.
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were analyzed by stratified log-rank test using age and
type of HSCT as covariates.
Sample Size
Based on a 1:1 randomization, an estimated 240
patients were required to reach a power of 80% to
show that the rate of treatment success for micafungin
is not\10% compared to itraconazole. The Chinese
State Food and Drug Administration require a mini-
mum of 100 patients to be enrolled in each arm of
a clinical study; it was therefore decided to enroll 125
patients in each treatment group.RESULTS
Patients
Patient data were collected between November
2008 and November 2009. A total of 287 patients
were enrolled and randomized (block randomization
resulted in an unequal number of patients allocated
to each treatment group; Figure 2). Of the randomized
patients, 136 and 147 patients received 1 dose of mica-
fungin or itraconazole, respectively, and had at least 1
endpoint measurement after receiving treatment; datafrom these patients were used to determine the
primary endpoint in the intent-to-treat population.
For the determination of the primary endpoint using
patients treated per protocol, data from 125
micafungin-treated patients and 103 itraconazole-
treated patients were available.
Both groups were broadly comparable at baseline
(Table 1). The age range of patients was 18 to 58 years.
Most commonly, patients in both groups received
HSCT for treatment of acute lymphocytic leukemia
(16% in both groups), acute myeloid leukemia (19%
in both groups), or chronic myeloid leukemia (14%
in both groups). The duration of neutropenia was
similar between the 2 arms (15 days in both groups),
but it was significantly different between autologous
versus allogeneic transplant recipients, being much
shorter in the autologous transplant group.
The mean (SD) duration of prophylactic antifun-
gal treatment was similar at 25 days (6.5) in the mica-
fungin group and 22.1 days (7.7) in the itraconazole
group.
Treatment Outcome
There were no statistically significant or clinically
meaningful differences between treatments in the rate
of patients without proven, probable, or suspected
Table 1. Baseline and Demographic Characteristics of
Recipients of SCT
Intent-to-treat population
Micafungin
(n 5 136)
Itraconazole
(n 5 147)
Gender
Male, n (%) 87 (64) 94 (63.9)
Female, n (%) 49 (36) 53 (36.1)
Age
Mean (SD), yr 32.1 (10.1) 33.3 (10.5)
18-49 yr, n 127 134
$50 yr, n 9 13
Transplant type
Autologous transplant, n (%) 24 (17.6) 32 (21.8)
Allogeneic transplant, n (%) 112 (82.4) 115 (78.2)
Period of neutropenia
Recovery achieved, n 121 130
Overall, median days (range) 15.0 (3-47) 15.0 (3-50)
Autologous transplant, median
days (range)
8.5 (4-41) 8.0 (4-23)
Allogeneic transplant, median
days (range)
15.0 (3-47) 17.0 (3-50)
SCT indicates stem cell transplant.
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gal treatment and without proven or probable invasive
fungal infection after completion of prophylactic treat-
ment (treatment success; Table 2). The difference
between the groups as determined by analysis of the
intent-to-treat was 22.04% with a 95% CI of
27.562% to 3.482% (P 5 .48). Outcomes in the 2
groups were similar using the per protocol set: the
difference between treatments was 20.861% (95%
CI, 27.489% to 5.767%). The analyses of the differ-
ence between therapies in both the intent-to-treat
and per protocol populations showed that the lower
boundary of the 95% CI was .210%, thereby dem-
onstrating the noninferiority of micafungin over
itraconazole.
Neither patient age nor type of SCT had an impact
of clinical meaning on differences between the 2 treat-
ments in the rate of patients without proven, probable,
or suspected invasive fungal infection (Table 2).
As shown in Table 3, there were no differences of
clinical meaning between micafungin and itraconazole
in the incidence of proven, probable, or suspected in-
vasive fungal infections occurring during prophylacticTable 2. Absence of Invasive Fungal Infections in All Patients and i
Intent-to-treat population
Micafungin (n 5 136) Itraconazole
No invasive fungal infection* 126 (92.6) 139
95% CI, 27.562 to 3.482
Age, 18-49 yr 118/127(92.9) 126/134
Age, $50 yr 8/9 (88.9) 13/13
Autologous transplant 22/24 (91.7) 32/32
Allogeneic transplant 104/112 (92.9) 107/115
CI indicates confidence interval.
*No proven, probable, or suspected invasive fungal infection during prophylactic
after completion of prophylactic treatment.therapy, after therapy, or at any time during the study.
The incidence of fungal infections occurring during
prophylactic treatment with either micafungin or itra-
conazole (treatment failure) was comparable at 7.4%
and 5.4%, respectively. The time to treatment failure
was also similar; Kaplan-Meier analysis showed no sig-
nificant difference between the treatments (P 5 .51)
nor was a significant difference found using Cox re-
gression analysis (P 5 .52; hazard proportion 0.74
[95% CI, 0.29% to 1.86%]).
One proven and 1 probable infection with Candida
were reported in the micafungin group. One probable
Aspergillus infection occurred in the itraconazole
group. All these infections occurred during prophylac-
tic treatment. One case of superficial fungal infection
was reported in the micafungin group.
There were no cases of proven or probable fungal
infection occurring after completion of prophylactic
treatment reported in patients who remained free of
infection during prophylactic treatment. A suspected
fungal infection, however, was reported in 4 of 126
micafungin-treated patients (3.2%) and in 5 of 139
(3.6%) itraconazole-treated patients after completion
of prophylactic treatment.
The use of systemic antifungal agents after pro-
phylactic administration of micafungin and itracona-
zole was similar in the 2 treatment groups. In the
micafungin group, 25.8% of patients (34 of 136 pa-
tients) received antifungal therapy, and in the itracona-
zole group, the rate was 24.3% of patients (35 of 147
patients).Colonization
Colonization at baseline was similar, with C. albi-
cans accounting for 0.7% of isolates in both treatment
groups. At the end of prophylactic therapy, C. albicans
was recovered from any site from 5.1% of
micafungin-treated patients (7 of 136 patients) and in
no itraconazole-treated patients. Incidents of coloniza-
tion with C. glabrata were low and similar between
micafungin-treated and itraconazole-treated patients
at 1.5% (2 of 136 patients) and 1.4% (2 of 147 patients),
and colonization with C. tropicalis was comparable at
0.7% in both groups (1 patient in each group). Then Prespecified Subgroups
Per protocol set
(n 5 147) Micafungin (n 5 125) Itraconazole (n 5 103)
(94.6) 115 (92) 96 (93.2)
95% CI, 27.489 to 5.767
(94) 108/117 (92.3) 85/92 (92.4)
(100.0) 7/8 (87.5) 11/11 (100)
(100) 18/20 (90) 23/23 (100)
(93) 97/105 (92.4) 73/80 (91.3)
antifungal treatment and no proven or probable invasive fungal infection
Table 4. Adverse Events by Study Group, Safety Set
Micafungin
(n 5 137)
Itraconazole
(n 5 147)
P
value*
Any event 60 (43.8) 83 (56.5) .033
Events with an incidence $3%
Diarrhea 8 (5.8) 14 (9.5)
Gastrointestinal disorder
(not classified)
12 (8.8) 22 (15)
Nausea 8 (5.8) 19 (12.9) .042
Vomiting 7 (5.1) 17 (11.6) .051
Pyrexia 23 (16.8) 20 (13.6)
Hyponatremia 6 (4.4) 1 (0.7)
Abnormal liver function test 9 (6.6) 7 (4.8)
Increased transaminase 5 (3.6) 9 (6.1)
Any drug-related event 11 (8.0) 39 (26.5) .000
Events with statistical difference
Gastrointestinal disorder 0 (0) 12 (8.2) .001
Nausea 0 (0) 9 (6.1) .004
Vomiting 0 (0) 8 (5.4) .007
Data are presented as n (%). Safety set: patients who had taken at least 1
dose of prophylactic antifungal therapy.
*Chi-square test.
Table 3. Incidence of Proven, Probable, or Suspected Invasive Fungal Infection
Intent-to-treat population Per protocol set
Micafungin (n 5 136) Itraconazole (n 5 147) Micafungin (n 5 125) Itraconazole (n 5 103)
Infection during prophylactic treatment
(treatment failure)
10 (7.4) 8 (5.4) 10 (8) 7 (6.8)
Proven infection 1 (0.7) 0 1 (0.8) 0
Aspergillosis 0 0 0 0
Candidiasis 1 (0.7) 0 1 0
Probable infection 5 (3.7) 2 (1.4) 5 (4) 2 (1.9)
Aspergillosis 0 1 0 1
Candidiasis 1 0 1 0
No mycological criterion 4 1 4 1
Suspected infection 4 (2.9) 6 (4.1) 4 (3.2) 5 (4.9)
Time to treatment failure, mean (SD), days 21.3 (6.1) 19.8 (6.7) 21.3 (6.1) 20.4 (6.9)
Infection after prophylactic treatment 4 (2.9) 5 (3.4) 4 (3.2) 5 (4.9)
Proven infection 0 0 0 0
Probable infection 0 0 0 0
Suspected infection 4 (2.9) 5 (3.4) 4 (3.2) 5 (4.9)
Infection at any time during the study 14 (10.3) 13 (8.8) 14 (11.2) 12 (11.7)
Proven infection 1 (0.7) 0 1 (0.8) 0
Probable infection 5 (3.7) 2 (1.4) 5 (4) 2 (1.9)
Suspected infection 8 (5.9) 11 (7.5) 8 (6.4) 10 (9.7)
Data are presented as n (%) unless otherwise indicated.
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1.5% (2 patients) of cases in the micafungin group.
The oropharynx was the most common site of coloni-
zation in themicafungin group (9 of 12 cases), followed
by the perirectum (2 cases) and in urine (1 case). The
perirectum/stool was the site of all 3 cases of coloniza-
tion in the itraconazole group.
Safety
There was 1 patient death in the itraconazole
group. The cause of death was pneumonia.
Tolerability of treatmentwas better in themicafun-
gin group, withmore patients in that group completing
the study (82.9% versus 67.3%) and a significantly
lower incidence of premature study withdrawal due
to an unacceptable toxicity (0.7% versus 19.7%;
P 5 .00, chi-square test) occurring in micafungin-
treated versus itraconazole-treated patients. Patients
withdrawn due to adverse events received an alternative
regimen, such as itraconazole i.v. formulation, flucona-
zole, voriconazole, or caspofungin.
Study drug administration was interrupted because
of adverse events for 2 itraconazole patients (1.4%).
The reasons for interrupting itraconazole were hemo-
lysis and gastrointestinal disorders (nausea, vomiting,
and diarrhea).
Adverse events were reported in significantly fewer
patients in the micafungin than in the itraconazole
group. Whereas the overall incidence of an adverse
event was 43.8% (60 of 137 patients) in micafungin-
treated patients, the incidence was 56.5% (83 of 147
patients) in the itraconazole group (P 5 .033, chi-
square test). There was also a significant difference
in the rate of investigator-identified, drug-related
adverse events, which was 8.0% in micafungin-treated patients (11 of 137 patients) and 26.5% in
itraconazole-treated patients (39 of 147 patients;
P 5 .000, chi-square test; Table 4). No serious drug-
related adverse events were reported in either group.
Serum creatinine increased slightly between base-
line and 4 weeks after prophylactic therapy in
micafungin-treated patients and decreased slightly in
itraconazole-treated patients. The change in median
(range) values in the micafungin group was 4.1 (230
to 121) mg/dL, and in the itraconazole group it was
26.0 (259 to 169) mg/dL. Values for total bilirubin
and BUN remained unchanged in both groups.
Alanine transaminase remained relatively stable with
micafungin (median [range] 1.0 [2164 to 317] IU/L)
but increased during the study with itraconazole (5.0
[2109 to 284] IU/L).
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This randomized study demonstrates the efficacy
of micafungin for antifungal prophylaxis in patients
with neutropenia. The rate of treatment success was
similar for micafungin and itraconazole in this popula-
tion of patients with neutropenia.
Our study compared the efficacy and safety of mi-
cafungin with that of itraconazole for prevention of in-
vasive fungal infection during neutropenia by means of
a design similar to that used by van Burik et al. [3],
which compared micafungin with fluconazole. In that
study, the overall rate of treatment success was signif-
icantly higher for patients treated with micafungin
(80%) than for patients treated with flucaonzole
(73.5%; 95% CI, 0.9%-12%; P 5 .03). In the study
by van Burik et al. [3], which included adult and pedi-
atric patients, the treatment success in adults was much
better than that in the pediatric population. However,
in our study, only adult patients were included. This
should be taken into consideration when comparing
the overall treatment success between the 2 studies.
The results we report for treatment success provide ev-
idence for the noninferiority of micafungin over itra-
conazole in preventing invasive fungal infections in
HSCT recipients. Even when the duration of neutro-
penia is taken into account, the results do not change.
However, in a post-hoc analysis, in which a com-
posite endpoint (no breakthrough fungal infections,
survival 7 days after the end of therapy, and no discon-
tinuation due to toxicity or lack of efficacy before re-
covery from neutropenia) for treatment success was
used, the results for the micafungin group are signifi-
cantly better than those for the itraconazole group
(91.9% [125 of 136] versus 74.1% [109 of 147]). In
our study, 29 patients were withdrawn due to toxicity
in the itraconazole group, whereas there was just 1 pa-
tient in the micafungin group, this being the most im-
portant reason for the marked difference.
Colonization with Candida species was 3-fold
higher in the micafungin than in the itraconazole
group, and the most common site of colonization
was the oropharynx in micafungin-treated patients.
The reason for this difference is unclear as micafungin
has demonstrated potent activity in vitro and in vivo
against all Candida species [7,8]. We speculate that
the oral solution formulation of itraconazole might
have provided greater benefit than the parenteral
formulation of micafungin in terms of preventing
oropharyngeal colonization.
The efficacy results of our study compare favorably
with those from 2 other studies of similar design, al-
though we administered micafungin at a lower daily
dose. We administered micafungin at a dose of 50
mg/day, and our rate of treatment success was about
93%. In comparison, in 2 studies conducted in Japan,
Hashino et al. [9] achieved an 88% rate of treatmentsuccess by administering micafungin at double our
daily dose (100 mg/day), and Hiramatsu et al. [10]
achieved a similar rate of treatment success (94%) by
administering micafungin at a substantially higher
daily dose (150 mg/day). At the same daily dose, the
rate of treatment success we found was higher than
that reported in the much larger randomized study
conducted by van Burik et al. [3].
Theprotocol-specifieddurationof prophylactic an-
tifungal treatment was #42 days, but the actual length
of treatment was much shorter in both groups at ap-
proximately 23 days.No cases of proven or probable in-
vasive fungal infection, only suspected cases, occurred
in either group after the administration of prophylactic
therapy. Of interest, empirical antifungal therapy was
administered to approximately one-quarter of patients
in each group. We did not collect information on the
reason for the administration of empirical therapy.
Antifungal prophylaxis is recommended for pa-
tients undergoing HSCT. Data from meta-analyses
of randomized studies indicate reductions in fungal-
related mortality, reductions in documented invasive
fungal infections, and reductions in empiric parenteral
antifungal therapy in patients who underwent
HSCT treated with antifungal prophylaxis [11,12].
Conflicting evidence exists over whether or not
antifungal prophylaxis positively impacts on mortality
from all causes. As we had a low number of deaths
and no deaths attributable to fungal infections, our
results would support a positive impact of antifungal
therapy on infection-related morbidity.
The benefit of prophylactic antifungal therapy
should outweigh any risk of adverse drug effects [13].
The results of this study provide further evidence for
the better patient tolerability of micafungin over
itraconazole. The incidence of adverse events, events
leading to premature study discontinuation, and events
causing discontinuation of the study drug were
significantly higher with itraconazole. Unfortunately,
the benefits of treatment with itraconazole are offset
by poor patient tolerance, and toxicity associated
with the solution formulation [1,2] and drug
discontinuation, especially due to nausea, is high [14].CONCLUSION
The results of this comparative study showed that
micafunginwas as effective as itraconazole in preventing
invasive fungal infection in recipients of a hematopoietic
SCT. Lower incidents of adverse events and premature
study withdrawal indicate better patient tolerability of
antifungal treatment withmicafungin over itraconazole.
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